Evaluation of Hepatic Impairment on Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964) in Healthy Adult Participants

The primary objective of this study is to evaluate the effect of **hepatic impairment** on the pharmacokinetics, safety, and tolerability of **Aticaprant** (JNJ-67953964) in healthy adult participants. Understanding the impact of liver function on the drug's behavior is clinically relevant as it informs dosing adjustments and safety considerations for patients with varying degrees of liver impairment. No secondary objectives are specified for this study.

The clinical trial involves a total of **12 participants** who are categorized as **healthy adult participants**. The study population includes both male and female subjects, with an age range that spans from young adults to middle-aged individuals. Participants were selected based on their general health status, ensuring they are free from any significant medical conditions. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The selection process included both male and female subjects, and the trial population is noted to include a **vulnerable population**. Specific inclusion or exclusion criteria were not provided by the sponsor.

The clinical trial is designed as an **open-label**, single-dose, parallel-group study to assess the effect of hepatic impairment on the pharmacokinetics, safety, and tolerability of Aticaprant (JNJ-67953964). The study will involve **healthy adult participants** and is categorized as a Phase 3 trial. The estimated recruitment start date is August 7, 2023, with an anticipated end date of January 24, 2024. The trial will not employ a **randomized** or **double-blind** design, as it is open-label, meaning both the researchers and participants will be aware of the treatment being administered.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will receive a single dose of the investigational product. Subsequent follow-up visits will be scheduled to monitor the pharmacokinetics, safety, and tolerability of the drug. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the study endpoints.

The expected length of participant involvement will span from the initial screening visit through to the end-of-study visit, aligning with the overall trial duration. Conditions that may lead to early termination from the study include adverse events, withdrawal of consent, or any protocol deviations that compromise the integrity of the trial. The study aims to provide valuable insights into the pharmacokinetic profile of Aticaprant in the context of hepatic impairment, contributing to the broader understanding of its safety and tolerability in this specific population.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on the administration of other medicinal products or their role in the trial.

Due to the lack of available data, further specifics on drug administration, dosing schedules, and participant compliance monitoring cannot be described. The absence of this information limits the ability to provide a comprehensive overview of the treatments involved in the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on August 7, 2023, with an estimated end date of January 24, 2024. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous clinical trial standards to ensure the reliability and validity of the efficacy outcomes. The trial's design and execution will be aligned with the regulatory requirements for Phase 3 clinical trials, focusing on the collection of robust data to support the evaluation of the investigational product's efficacy.